105 related articles for article (PubMed ID: 12378574)
1. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates?
Spencer K; Cuckle HS
Prenat Diagn; 2002 Oct; 22(10):903-6. PubMed ID: 12378574
[TBL] [Abstract][Full Text] [Related]
2. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
4. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
5. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
6. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
[TBL] [Abstract][Full Text] [Related]
7. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
8. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
9. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
10. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
11. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
12. Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
Spencer K; Talbot JA; Abushoufa RA
Prenat Diagn; 2002 Aug; 22(8):656-62. PubMed ID: 12210572
[TBL] [Abstract][Full Text] [Related]
13. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
14. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K; Ong C; Skentou H; Liao AW; H Nicolaides K
Prenat Diagn; 2000 May; 20(5):411-6. PubMed ID: 10820411
[TBL] [Abstract][Full Text] [Related]
15. Comparison of serum markers in first-trimester down syndrome screening.
Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
[TBL] [Abstract][Full Text] [Related]
16. One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
Nicolaides KH; Bindra R; Heath V; Cicero S
J Matern Fetal Neonatal Med; 2002 Jul; 12(1):9-18. PubMed ID: 12422904
[TBL] [Abstract][Full Text] [Related]
17. Prospective study evaluating performance of first-trimester combined screening for trisomy 21 using repeat sampling of maternal serum markers PAPP-A and free β-hCG.
Ekelund C; Wright D; Ball S; Kirkegaard I; Nørgaard P; Sørensen S; Friis-Hansen L; Jørgensen FS; Tørring N; Bech BH; Petersen OB; Tabor A
Ultrasound Obstet Gynecol; 2012 Sep; 40(3):276-81. PubMed ID: 22807155
[TBL] [Abstract][Full Text] [Related]
18. First-trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A can detect triploidy and determine the parental origin.
Yaron Y; Ochshorn Y; Tsabari S; Shira AB
Prenat Diagn; 2004 Jun; 24(6):445-50. PubMed ID: 15229844
[TBL] [Abstract][Full Text] [Related]
19. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K; Nicolaides KH
Prenat Diagn; 2002 Oct; 22(10):877-9. PubMed ID: 12378569
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss.
Goetzl L; Krantz D; Simpson JL; Silver RK; Zachary JM; Pergament E; Platt LD; Mahoney MJ; Wapner RJ
Obstet Gynecol; 2004 Jul; 104(1):30-6. PubMed ID: 15228997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]